Literature DB >> 20549841

Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients.

Nadia Valin1, Jérôme Pacanowski, Lise Denoeud, Karine Lacombe, Valérie Lalande, Laurent Fonquernie, Pierre-Marie Girard, Jean-Luc Meynard.   

Abstract

OBJECTIVE: To determine characteristics and risk factors for unmasking tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRIS) following initiation of combination antiretroviral therapy (cART) in HIV-infected patients, which have not yet been assessed to date.
DESIGN: Retrospective single-center cohort study.
METHODS: Medical records of HIV-infected patients diagnosed with tuberculosis following cART initiation were reviewed. Cases of unmasking IRIS were identified using provisional consensus definitions. Characteristics of patients with and without unmasking TB-IRIS were compared. A case-control design was used to identify risk factors for unmasking TB-IRIS in patients initiating cART.
RESULTS: Among 47 patients on cART at TB diagnosis, 11 experienced unmasking IRIS (23%). They had lower CD4% (9 vs. 14, P=0.02), higher HIV-RNA load at baseline (5.2 vs. 4.0 log, P=0.005), and a stronger CD4% increase with HIV-RNA decline after 1 month on cART (+7 vs. +3 log, P=0.02, and -3.2 vs. -0.8 log, P=0.005) than the 36 remaining patients without unmasking IRIS. In the case-control study, risk factors for unmasking IRIS were African country of origin (65 vs. 18%, P=0.007), higher baseline HIV-RNA load (5.2 vs. 4.7 log, P=0.01), stronger CD4% increase (+7 vs. +2, P=0.0001), and HIV-RNA decline of more than 3 log after 1 month on cART (73 vs. 27%, P=0.02).
CONCLUSION: Patients with African origins, advanced HIV infection, or a strong response to cART are at greater risk of unmasking TB-IRIS.

Entities:  

Mesh:

Year:  2010        PMID: 20549841     DOI: 10.1097/qad.0b013e3283396007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

Review 2.  Timing of antiretroviral therapy for HIV in the setting of TB treatment.

Authors:  Damani A Piggott; Petros C Karakousis
Journal:  Clin Dev Immunol       Date:  2010-12-27

3.  Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.

Authors:  William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders
Journal:  Clin Dev Immunol       Date:  2010-12-08

Review 4.  Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

Authors:  N Kumarasamy; Atul Patel; Sanjay Pujari
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

5.  Immune reconstitution inflammatory syndrome and the influence of T regulatory cells: a cohort study in The Gambia.

Authors:  Irfan Zaidi; Kevin Peterson; David Jeffries; Hilton Whittle; Thushan de Silva; Sarah Rowland-Jones; Assan Jaye; Bouke C de Jong
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

Review 6.  Tuberculous meningitis in patients infected with human immunodeficiency virus.

Authors:  Ravindra Kumar Garg; Manish Kumar Sinha
Journal:  J Neurol       Date:  2010-09-17       Impact factor: 6.682

7.  The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Authors:  Naomi F Walker; Cari Stek; Sean Wasserman; Robert J Wilkinson; Graeme Meintjes
Journal:  Curr Opin HIV AIDS       Date:  2018-11       Impact factor: 4.283

8.  Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.

Authors:  Lewis John Haddow; Mahomed-Yunus Suleman Moosa; Anisa Mosam; Pravi Moodley; Raveen Parboosing; Philippa Jane Easterbrook
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

9.  Tuberculous meningitis: diagnosis and treatment overview.

Authors:  Grace E Marx; Edward D Chan
Journal:  Tuberc Res Treat       Date:  2011-12-21

10.  The aware, alert, avert strategy for immune reconstitution inflammatory syndrome in HIV/AIDS.

Authors:  Udhayvir Singh Grewal
Journal:  J Res Med Sci       Date:  2017-08-16       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.